Temporal Requirements of cMyc Protein for Reprogramming Mouse Fibroblasts by Heffernan, Corey et al.
Hindawi Publishing Corporation
Stem Cells International
Volume 2012, Article ID 541014, 12 pages
doi:10.1155/2012/541014
Research Article
Temporal Requirements of cMyc Protein for
ReprogrammingMouseFibroblasts
Corey Heffernan,1 HuseyinSumer,1 LuisF. Malaver-Ortega,1 and Paul J. Verma1,2
1Cell Reprogramming and Stem Cells Laboratory, Centre for Reproduction and Development, Monash Institute of Medical Research,
Monash University, 27-31 Wright Street, Clayton, VIC 3168, Australia
2South Australian Research and Development Institute, Turretﬁeld Research Centre, Rosedale, SA 5350, Australia
Correspondence should be addressed to Paul J. Verma, paul.verma@monash.edu
Received 9 November 2011; Revised 9 January 2012; Accepted 9 January 2012
Academic Editor: Rajarshi Pal
Copyright © 2012 Corey Heﬀernan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Exogenous expression of Oct4, Sox2, Klf4, and cMyc forces mammalian somatic cells to adopt molecular and phenotypic char-
acteristics of embryonic stem cells, commencing with the required suppression of lineage-associated genes (e.g., Thy1 in mouse).
Although omitting cMyc from the reprogramming cocktail minimizes risks of uncontrolled proliferation, its exclusion results in
fold reductions in reprogramming eﬃciency. Thus, the feasibility of substituting cMyc transgene with (non-integrative) recom-
binant “pTAT-mcMyc” protein delivery was assessed, without compromising reprogramming eﬃciency or the pluripotent phe-
notype. Puriﬁcation and delivery of semisoluble/particulate pTAT-mcMyc maintained Oct4-GFP+ colony formation (i.e., repro-
gramming eﬃciency) whilst supporting pluripotency by various criteria. Diﬀerential repression of Thy1 by pTAT-mcMyc±Oct4,
Sox2, and Klf4 (OSK) suggested diﬀerential (and non-additive) mechanisms of repression. Extending these ﬁndings, attempts
to enhance reprogramming eﬃciency through a staggered approach (prerepression of Thy1) failed to improve reprogramming
eﬃciency. We consider protein delivery a useful tool to decipher temporal/molecular events characterizing somatic cell
reprogramming.
1.Introduction
Forced expression of four key transcriptional regulators,
Oct4, Sox2, Klf4, and cMyc, converts mammalian somatic
cells to “induced pluripotent stem cells” (iPSCs), that satisfy
all pluripotent criteria of embryonic stem (ES) cells [1–3].
The reprogramming of ﬁbroblasts occurs sequentially, com-
mencing with requisite suppression of lineage-associated
genes [4, 5]; Thy1 (CD90) is a glycosylphosphatidylinositol-
anchored plasma membrane glycoprotein expressed in mu-
rine ﬁbroblasts and commonly used as a lineage gene marker
in reprogramming literature [5–7]. Although required for
endogenous lineage gene suppression [8], exogenous cMyc
expression is dispensable for the induction of pluripoten-cy,
and its omission from the reprogramming cocktail favour-
able given its link to oncogenesis. However, fold-reductions
in reprogramming eﬃciency commonly result (potentially
due to maintenance of endoderm gene regulators and failure
to activate microRNA clusters beneﬁcial to reprogramming;
[9–11]). Thus, application of nonintegrative cMyc con-
ceptually circumvents risks of oncogenesis whilst utilising
beneﬁcial eﬀects in regards to lineage gene suppression.
Application of fusion protein incorporating (i) a cationic
polyarginine tag (for transduction across plasma mem-
branes) and (ii) cMyc sequence, in combination with the
otherreprogrammingproteins,totargetcellsinvitrosuccess-
fully reprograms murine and human cells to pluripotency
[12, 13]. These studies puriﬁed denatured protein from
bacterial inclusion bodies before refolding and applica-
tion to target cells (micromolar concentrations) [12], or
applied unknown concentrations of whole protein extract
from induced human cells without puriﬁcation [13]. Initial
attempts to purify recombinant proteins incorporating (i)
reprogramming factor domains fused to (ii) a similarly
arginine-rich basic domain (49RKKRRQRRR57)o fH I V
transactivating transcriptional-activator (Tat) protein from2 Stem Cells International
bacterial inclusion bodies under denaturing conditions en-
c o u n t e r e dp r o b l e m sw i t hr e s t r i c t i o nt oe n d o s o m e si nt a r -
get cells following transduction [14]. Binding of the Tat
transduction domain to plasma membrane-bound heparan
sulfate proteoglycans initiates transduction through caveolar
(“lipid raft”) endocytosis; translocation to the nuclear com-
partment soon follows via an importin protein-independent
mechanism [15–20]. However, subsequent studies have
demonstrated cytoplasmic release of active recombinant
protein [21].
Here, we implemented a similar strategy to dissect the
early molecular mechanisms of iPSC derivation, namely, the
contribution of each reprogramming factor in suppression
of the murine ﬁbroblast lineage gene Thy1 that characterizes
reprogrammingoftransgenic(Oct4-GFP)mouseembryonic
ﬁbroblasts to iPSC [22] and exploited the ease of manip-
ulation of protein delivery to attempt to maximize repro-
gramming eﬃciency through a staggered approach of repro-
gramming factor expression/exposure. Conceptually, advan-
tages associated with utilizing protein delivery to dissect
molecular mechanisms of reprogramming include its ready
reversibility, allowing transient treatment of known and/or
bolus quantities of protein, and the ability to circumvent the
lag in transcription and translation inherent in constitutive
and inducible proviral strategies. We further describe an
alternative (fusion) protein puriﬁcation approach, purifying
and concentrating soluble (nondenatured) pTAT-mcMyc
protein from induced bacterial cells, and deliver particulate/
semisoluble protein of known concentrations.
2.MaterialsandMethods
2.1. Materials. A l lr e a g e n t sw e r ep u r c h a s e df r o mS i g m a -
Aldrich(CastleHill,NSW,Australia)unlessotherwisestated.
All sequencing was performed at the Gandel Sequencing
Facility, Monash Institute of Medical Research, Australia.
2.2. Methods
2.2.1. Mice and Animal Ethics. Experiments were approved
by the Monash University Animal Ethics Committee and
satisﬁed Australian National Health and Medical Research
Council(NH&MRC)guidelinesforanimalexperimentation.
MEF were harvested from 13.5dpcOG2× OG2 mice har-
boring a GFP reporter expressed from Oct4 proximal and
distal enhancers and the Oct4 promoter proper [23]. All
experiments were conducted using MEF passage 3.
2.2.2. Construction of Tat Expression Vectors. PCR products
were ampliﬁed (High Fidelity PCR protocol; Roche,
Australia) from pMXs plasmid template encoding cDNA for
mouse cMyc (mcMyc; Addgene, USA). Primers contributed
restriction enzyme digest sites with adjacent linker DNA and
stop sequences (where applicable) to PCR product (outlined
by supplemental Figure 1C of the supplementary material
available online at doi: 10.1155/2012/541014). Ampliﬁed
PCR products and pTAT expression vector (generously pro-
vided by Dr Stephen F. Dowdy, University of California/
Howard Hughes Medical Institute, USA) underwent
overnight digestion (4◦C) with restriction enzymes EcoR1
and Xho1 (Biolabs, Australia) before agarose gel puriﬁcation
and isolation (QIAgen Australia). Digested PCR products
and pTAT plasmid were ligated with T4 DNA ligase (Pro-
mega, Australia) via manufacturer’s conditions (overnight,
4◦C), before electro-transformation to DH10B competent
cells (BioRAD, Australia). Transformation preparations were
spread to agar plates under 50μg/mL kanamycin selection
and clones screened for successful ligation by sequencing
(T7 sequencing primer).
2.2.3. Expression, Puriﬁcation, and Concentration of 6XHis-
Tagged, pTAT-mcMyc Fusion Protein. Ligated pTAT-mcMyc
plasmid, and native pTAT plasmid (control) were electro-
transformed to BL21 (DE3) competent cells (Stratagene,
USA) and spread on agar under kanamycin selection. Clones
were expanded in LB Broth (made in house) containing
kanamycin selection and sequenced again. Protein expres-
sion was performed by 0.1mM isopropyl β-D-thiogalactosi-
dase-(IPTG-)induced protein expression (230rpm agitation
overnight, 37◦C). Initially, we puriﬁed soluble and insoluble
(requiring puriﬁcation of denatured protein) fractions of
pTAT-mcMyc and control pTAT protein before analysis by
WesternBlot(puriﬁedNi-NTAcolumns;QIAgen,Australia).
We conﬁrmed pTAT-mcMyc protein predominantly present
in the soluble fraction by Western Blot (outlined below).
To purify soluble pTAT-mcMyc and pTAT control pro-
teins, bacteria were lysed (1% Triton X-100, 0.1mg/mL
Lysozyme in 50mM NaH2PO4, 300mM NaCl, 10mM imid-
azole, pH 8.0) and incubated at 37◦Cf o r1h o u r ,a n do ni c e
for 30mins. RNase (5μg/mL; Invitrogen, Australia), DNase
(2units/mL; Promega, Australia) in 1mM MgCl2 and phe-
nylmethylsulfonyl ﬂuoride (1mM) were added before son-
ication on ice. Cells were further homogenized through
a 23-gauge needle before centrifugation (9000xg, 30mins,
4◦C). The supernatant was collected for puriﬁcation/elution
through Ni-NTA columns via manufacturer’s instructions.
To concentrate protein preparations, four-part ice-cold
acetone was added to one part puriﬁed protein (v/v) and
incubated at −20◦C for 30–45 minutes. Following centrifu-
gation at 6800xg for 10 minutes (4◦C), proteins pellets were
resuspended in 50μL sterile H2O or PBS. Molar concen-
trations of proteins were calculated against known protein
standards with the colorimetric BioRAD D
C Protein Assay
(for pTAT control protein; BioRAD, Australia), or by protein
spectrophotometry (for pTAT-mcMyc).
2.2.4. Western Blot. Reduced and denatured pTAT-mcMyc
and control pTAT protein was electrophorated (90V, ∼2
hour, 4◦C) through 12–15% denaturing polyacrilymide gel
and either (a) ﬁxed in 10% methanol /7% acetic acid before
staining with SYPRO Ruby whole protein stain (BioRAD,
Australia) and visualization under UV light, or (b) blotted to
PVDF membrane (Millipore, Australia). Blotted wet mem-
brane was blocked with Odyssey blocking Buﬀer (Odyssey,
Australia) and probed with anti-6xHis-tag primary antibody
(1:2500; Sapphire/Abcam, Australia) or anti-mcMyc (tar-
get sequence CSTSSLYLQDLSAAASEC) primary antibody
(1:50, Sapphire/Abcam, Australia). Primary antibodies wereStem Cells International 3
detected with the anti-mouse Alexa ﬂuor-680 secondary
antibody (Molecular Probes; Invitrogen, Australia) for 1h
at room temperature. Test and negative control membranes
(secondary antibody only) were visualized on an Odyssey
InfraRed Imager (LI-COR Biosciences, Lincoln, NE, USA;
intensity: 3–10, quality: medium, resolution: 169). Visual-
ized protein bands were compared to predicted molecular
weights for each protein calculated with EXpasy Software
(http://web.expasy.org/compute pi/).
2.2.5. Immunocytochemistry. To conﬁrm translocation of
pTAT-mcMyc and pTAT control protein to the nuclear
compartment of treated cells, we performed ﬂuorescent
immunocytochemistry according to standard methods. 2 ×
104 MEF were plated to coverslips before 100nM pTAT-
mcMyc or pTAT control protein was applied and incubated
at 37◦Cf o r1h o u r[ 24]. Cells were extensively washed in
PBS, ﬁxed in 4% paraformaldehyde (prepared inhouse) and
blocked in 2.5% skim milk/2.5% goat serum/PBS before
labeling with 6xHis (1:1500; Sapphire/Abcam, Australia).
For conﬁrmation of expression of pluripotency markers,
iPSCs were labeled with SSEA1 (dilution 1:100; Chemi-
con/Millipore, Australia). Bound primary antibody was
detected with Alexa Fluor 488 or 555 (1:1500; Molecular
Probes/Invitrogen, VIC, Australia). Cell nuclei were detected
with 1mg/mL Bisbenzimide Hoechst 33342. Images were
taken using confocal microscope with FluorView software
( v e r s i o n1 . 5o r4 . 5 ) .
2.2.6. Induction of Pluripotency in MEF OSK ± pTAT-cMyc
Protein Treatment. iPSCs were derived from OG2 MEF via
established protocols, using pMXs retroviral vectors [1, 22].
Brieﬂy, 3.8 × 104 MEF (12-well plates) were infected with
retrovirus harboring mOct4, mSox2, mKlf4 (denoted OSK
forthwith) ± mcMyc packaged in Platinum-E cell [25].
Parallel infection of MEF with a GFP-reporter transgene
conﬁrmed ≥80% infection eﬃciency. One-part FP media
(10% (v/v) fetal bovine serum (FBS; JRH, Australia), 0.5%
(v/v) penicillin/streptomycin in DMEM) replaced mcMyc
retrovirus where applicable. After 24-hour incubation, virus
containing media was replaced with standard ES cell culture
media (designated day 0, see Figure 2(a); 15% FBS, 1% (v/v)
Non-essential amino acids (Invitrogen, Australia), 1% (v/v)
glutamax (Gibco, Australia), 0.1% (v/v) β-mercaptoethanol
(Gibco, Australia), and mouse LIF (Millipore/Chemicon,
Australia).ESmediawaschangeddailyfor12days.Atday12,
suitable clones of each condition were picked and expanded
for future analysis.
To avoid pH-related protein denaturing events, ES media
wasequilibratedat37◦C/5%CO2 for ≥1hourbefore100nM
semisoluble pTAT-cMyc or control protein was added to
applicable conditions. On days 5, 7, 9, and 12 after infection
(PI), Oct4-GFP+ colonies were counted or cells collected for
ﬂow cytometry (outlined below).
2.2.7. Alkaline Phosphatase Expression Analysis. Alkaline
phosphatase expression was conﬁrmed in 4% paraformalde-
hyde ﬁxed iPSCs colonies via standard protocols (Millipore,
Australia).
2.2.8. Teratoma Formation Assay: Hind Leg Injection. Ap-
proximately 1 × 106 iPSCs (clone TATc1) were injected into
the hind leg of 2x SCID mice. Teratomas were harvested
6–8 weeks after injection and sectioned for haemotox-
ylin/eosin staining (Histology Facility, MIMR) and visualiza-
tion.
2.2.9. Flow Cytometry. Detached cells were blocked in block-
ing buﬀer(1-2% bovine serum albumin/PBS)for15 minutes
at room temperature before primary antibody was added
(4.8μg/mL Thy1-PE; eBioscience, Australia). Following 30–
45 minute incubation, cells were washed 3 times in blocking
buﬀer and resuspended in PBS (without Ca2+/Mg2+). Flow
cytometry and analysis was performed on Becton Dickinson
BDCanto II Flow cytometer (Becton Dickinson, Australia).
2.2.10. Embryo Aggregation. Zygotes (0.5dpc) were isolated
from ampullae of mated female F1 m i c ea n dc u l t u r e di n
droplets of KSOM media (Chemicon/Millipore, Australia)
until they developed to the compacted morula stage at
2.5dpc. Zona pellucidae were digested from embryos with a
short incubation in Acid Tyrodes solution (pH 2.5) before
aggregation with 10–15 TATc1 iPSC in depressions in cul-
ture dishes formed with darning needles [26]. Embryo/cell
aggregates were cultured until blastocyst stage (4.5dpc) and
assessed for contribution of GFP+ cells to inner cell mass of
aggregated embryos.
2.2.11. Mycoplasma Testing. Culture media was supple-
mented with 100nM pTAT-mcMyc or pTAT-control and
incubated for 24 hours at 37◦C. Media was collected and
tested for the presence of mycoplasma. Mycoplasma testing
was performed with MycoAlert Mycoplasma Detection kit
(Lonza Rockland Inc, ME USA) at MIMR Histology Core
facility.
2.2.12. Statistical Analysis. Where variances of OSKM and
other treatment groups were suﬃciently diﬀerent (Tukey’s
test), one-way ANOVA was performed on log-transformed
data. Means of duplicate wells for experimental repeats of
OSK and OSK + pTAT-mcMyc (Figure 2(d)) indicated with-
in-day variability. One-way ANOVA was performed on raw
data (equal variances) or log-transformed data (unequal var-
iances) for normalized Thy1+ cells of each treatment group
(http://faculty.vassar.edu/lowry/t ind stats.html).
3. Results
3.1. Individual, and Combinations, of Reprogramming iPSC
F a c t o r sD o w n r e g u l a t eT h y 1t oV a r y i n gD e g r e e s . To highlight
the eﬀect of each combinations of reprogramming factor/s
to Thy1 repression over 12 days, MEFs were infected with
retrovirus harboring transgenes for individual or combi-
nations of reprogramming factors before assessment for
Thy1 expression by ﬂow cytometry at day 12 (n = 3–5).
Unsurprisingly, OSKM-expressing cells almost totally down-
regulated Thy1 over 12 days. All individual reprogramming
factors, and combinations of ≤3 factors, suppressed Thy1
between approximately 50 and 75% of MEF over 12 days4 Stem Cells International
(Figure 1),althoughinsigniﬁcantlydiﬀerentfromeachother.
Although OSKM expression almost entirely extinguished
Thy1 expression over 12 days, the capacity of individual
Klf4 or cMyc factors to suppress Thy1 was not signiﬁcantly
enhancedwhenbothfactorswerecombinedwitheitherOct4
or Sox2. Similarly, no additive Thy1 repression was observed
when Oct4 and Sox2 factors were combined, or when cMyc
and Klf4 were expressed in the same MEF (Figure 1). This
suggests that maximal Thy1 repression can only be achieved
in the presence of all four reprogramming factors, and not
≤3f a c t o r s( Figure 1).
3.2. Construction of pTAT-mcMyc Expression Vector and Sub-
sequent Protein Expression. Control over expression levels,
as well as timing of expression, is limited using retroviral
strategies. Therefore we adopted a recombinant protein
strategy to dissect the molecular and temporal mechanisms
of reprogramming. We ampliﬁed cDNA for mouse cMyc
(mcMyc)ﬂankedbyanN-terminalEcoRIrestrictionenzyme
digest site and a C-terminal XhoI site (linked by a single
guanine to maintain in-frame mcMyc sequence; primers
outlined in supplemental Figure 1(C)). Following direct
restriction digestion of PCR products and subsequent DNA
ligation, sequencing conﬁrmed successful, in-frame ligation
of mcMyc cDNA insert to digested pET28b TAT plas-
mid; denoted pTAT-mcMyc forthwith (Figure 2(a)). pTAT-
mcMyc and empty vector (control) plasmid were trans-
formed to BL21(DE3) cells for IPTG-induced protein
expression. We initially puriﬁed pTAT-mcMyc protein under
either soluble or insoluble (denaturing) conditions and
employed SDS-PAGE to conﬁrm which fraction the recom-
binant proteins (of predicted molecular weight) was present
in (predicted pTAT-mcMyc 53.05kDa; EXpasy software;
http://web.expasy.org/compute pi/). Protein concentration
wasequatedbycolorimetricproteinassayorspectrophotom-
etry before freezing aliquoted protein. Reduced and dena-
tured pTAT-mcMyc protein (of both purifying preparations)
was electroporated through 12–15% polyacrilymide gel and
blotsprobedwithantibodiesrecognizingeither(i)the6xHis-
tidine leader sequence (Figure 2(b) and supplemental Figure
1(A)), or (ii) amino acids 186–203 of mouse/human mcMyc
(Figure 2(b)). Contrary to previous reports, we detect-ed
a primary band of puriﬁed, histidine-tagged pTAT-mcMyc
protein close to predicted molecular weight primarily in the
soluble fractionusing antibody detecting the leader sequence
(Figure 2(b)), with little detectable protein in denaturing
conditions (supplemental Figure 1(A)). To conﬁrm speciﬁc-
ity of our anti-Histidine antibody, western blots were repeat-
ed using antibody directed against mouse/human cMyc;
again, protein was detected at the same MW (Figure 2(b)).
Expression of control protein of predicted molecular weight
(6.099kDa)wasconﬁrmedbyHis6 leadersequencedetection
(data not shown). These results suggest successful construc-
tion, expression, and puriﬁcation of semisolubilized, partic-
ulate pTAT-mcMyc and pTAT-control protein close to pre-
dicted molecular weight in our bacterial expression system.
Initial experiments conﬁrmed the pH of culture media
reduced in alkalinity to near neutral after 1-hour incuba-
tion at 37◦C/5% CO2. Therefore, to avoid denaturation
of recombinant protein upon application to acidic culture
media, neutrality was established prior to application of
pTAT-mcMyc application by 1 hour incubation at 37◦C/5%
CO2. To ascertain whether eluted pTAT-mcMyc protein (and
pTAT control protein) can transduce to the nucleus of MEF,
100nM of pTAT-mcMyc (or 100nM control protein) was
added to cultures of MEF grown on coverslips and incu-
bated for 1 hour. A concentration of 100nM was adopted
from a survey of previous reports for TAT fusion protein
delivery [27–30]. Fixed and permeabilized cells were labeled
with antibody recognizing the 6xHistidine sequence. pTAT-
mcMyc and pTAT-control proteins were detected primarily
conﬁned to the nuclear compartment of treated MEF, (com-
pare “Nuclei” and “6xHis Detection” panels; Figure 2(c)).
Minimal protein was observed in cytoplasm/cytoplasmic
vesicles, perhaps reﬂective of recombinant TAT protein with-
in cytoplasmic endosomes or in transit to the nucleus (red
arrows, Figure 2(c);[ 15]). Detection of antibody binding in
nontreated cells was minimal, suggesting minimal nonspe-
ciﬁcbindingofantibodytoalternativehistidine-richproteins
(datanotshown).Theseresultsconﬁrmrapid(≤1hour)and
eﬃcient transduction of pTAT-mcMyc (and control pTAT
protein) to nuclear compartment of MEF.
3.3. Addition of pTAT-mcMyc Protein to OSK Provirus-
ExpressingCellsAcceleratesOct4-GFP+ ColonyFormationover
12 Days (after Infection). A delayed and reduced eﬃciency of
iPSC colony formation is observed when cMyc is omitted
from the reprogramming factor cocktail [9]. We hypoth-
esized that the addition of the pTAT-mcMyc recombinant
protein to OSK-expressing MEF would result in a signiﬁcant
increase in Oct4-GFP+ colony formation. In our hands,
Oct4-GFP+ iPSC colony formation in OSKM provirus ex-
pressing MEF was comparable to OSK-expressing cells up to
12 days, only surpassing OSK colony formation after 12 days
(data not shown). Therefore, we infected Oct4-GFP trans-
genic MEF with retrovirus harboring transgenes for either
OSK or mcMyc alone and examined OSK ± pTAT-mcMyc
over 12 days. In four separate experiments, we added either
100nM pTAT-mcMyc or pTAT control protein to duplicate
wellsofOSK-expressingMEFdailyfor12daysandcompared
Oct4-GFP+ colony counts to OSK-expressing MEF at days 5,
7, 9, and 12 after infection (n = 4; Figure 2(d)). The addi-
tion of pTAT control protein to OSK-infected cells did not
elicit signiﬁcant improvements in Oct4-GFP+ colony forma-
tion over OSK-infected cells at anytime point, suggesting the
Tat and linker protein sequences had little eﬀect on Oct4-
GFP+ colony formation (see green line, Figure 2(d)). MEF
treated exclusively with 100nM pTAT-mcMyc protein alone
(Figure 2(d)) and mcMyc transgene-expressing MEF (data
not shown) failed to generate colonies at any time points.
Statistically signiﬁcant improvements in Oct4-GFP+ colony
formation were observed at day 7 and 9 after infection (P<
0.05 and P<0.005, resp.) in OSK-expressing cells treated
with 100nM pTAT-mcMyc protein. This suggests that nu-
clear-localized pTAT-mcMyc protein is biologically func-
tional and can accelerate iPSC colony formation in OSK
MEF.Stem Cells International 5
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Figure 1: Contribution of individual reprogramming factors to
repression of Thy1. MEFs were infected with either all four
reprogramming factors (OSMK), individual reprogramming fac-
tors (mOct4 or mSox2 or mcMyc, or mKlf4), or combinations of
reprogrammingfactors(mcMyc&mKlf4,OS,OMK,SMK).Onday
12 after infection, the percentage of cells expressing the ﬁbroblast
marker Thy1 was assessed by ﬂow cytometry in all treatment
groups.MeanpercentageThy1+ cells,normalizedtountreatedMEF
controls (black bar) of n = 5 experiments ± SEM are shown.
Statistical signiﬁcance established by one-way ANOVA, with “a”
denoting groups insigniﬁcantly diﬀerent from each other.
3.4. Conﬁrmation of Pluripotency of OSK+ pTAT-mcMyc-
Treated Cells. We expanded 3 × Oct4-GFP+ clones from
experiment outlined in Figure 2(d), of which one cell line is
chosenonproliferativeandmorphologicalcharacteristicsfor
further analysis (denoted TATc1 forthwith; Figure 3(B). We
assessed the pluripotency of the TATc1 cell line by standard
pluripotency criteria. We conﬁrmed that colonies express
alkaline phosphatase (Figure 3(C)). We conﬁrmed this clone
was not contaminated with mcMyc transgene by PCR using
genomic DNA template (“T”gene” in Figure 3(D)) and con-
ﬁrmed expression of endogenous Oct4, Sox2, Klf4, cMyc,
Rex1, and Nanog (“Endo” in Figure 3(D)). Histological in-
spection of teratomas formed from intramuscular injection
of TATc1 into the hind leg of SCID mice highlighted regions
of diﬀerentiation characteristic of all three cell lineages,
cartilage characteristic of mesoderm, glandular tissue rem-
iniscent of endoderm, and neural rosettes characteristic of
ectoderm (Figure 3(E)). Immunocytochemistry conﬁrmed
that compact TATc1 (Oct4-GFP+) colonies coexpress stage-
speciﬁc embryonic antigen-1 SSEA1 (Figure 3(F)). TATc1
cells retained normal karyotype during the reprogramming
period (passage 5, 20/20 counts 40XY; Figure 3(G)) and
contributed to the inner cell mass of developing blasto-
cysts when aggregated with diploid F1 4–8 cell embryos
(Figure 3(H)). Collectively, these results conﬁrm that
OSK+pTAT-mcMyc-treated cells share the hallmarks of
pluripotency observed in OSKM- and OSK-induced cells
[1, 9].
3.5. Addition of pTAT-mcMyc to OSK Provirus-Expressing
Cells Augments Downregulation of Thy1 over 12 Days after
Infection. All individual reprogramming factors can repress
lineage gene expression (i.e., Thy1) over a 12 days period,
with ≥5 days of initial cMyc expression required for eﬃcient
AP+ colony formation (Figure 1)[ 8]. Hence, we adopted a
recombinant protein delivery approach to dissect the tem-
poral and molecular mechanisms of somatic cell reprogram-
ming, primarily repression of Thy1 [12, 31]. In an indepen-
dent experiment, we collected experimental groups on days
5,7,9,and12(n = 3)toassessthepercentageofcellsexpress-
ing the Thy1 by ﬂow cytometry, normalizing results to
untreated MEF controls (39.2 ± 4.7%, mean ± SEM in our
hands; Figure 4). A gradual downregulation of Thy1 was
observed in OSK expressing cells over 12 days post infection
(Figure 4). Application of 100nM pTAT-mcMyc protein
alone to MEF elicited a signiﬁcant downregulation of Thy1
over the initial 5-day treatment period, which was main-
tained, from 5 to 12 days (Figure 4; P<0.05). Improved
(although not signiﬁcant) Thy1 repression continued to 7
days in MEF expressing OSK and treated with 100nM pTAT-
mcMyc protein, with Thy1 repression maintained to 12 days
after infection (Figure 4). Mycoplasma testing of protein-
treated culture media conﬁrmed Thy1 repression was not
due to contaminating mycoplasma from protein puriﬁcation
(data not shown).
3.6. Five-Day Pretreatment of OG2 MEF with pTAT-mcMyc ±
Exogenous mKlf4 Expression for Subsequent mOct4/mSox2-
Mediated Reprogramming. Lineage gene repression early
in reprogramming is a prerequisite for pluripotency gene
activationlateinreprogramming[4,5].Thedispensabilityof
cMycfromtheinitial5daysofreprogrammingsuggestsarole
in lineage gene repression for this reprogramming factor [8].
Since signiﬁcant Thy1 repression results from pTAT-mcMyc
recombinant protein application (in presence or absence of
Klf4expression;Figure 4),weproposedastaggeredapproach
to initiating reprogramming; a 5-day pretreatment (and
therefore “prerepression” of Thy1) of MEF with Klf4 ± 100
nM pTAT-mcMyc recombinant protein could facilitate sub-
sequent accelerated Oct4 + Sox2-mediated reprogramming
(assessed by Thy1 downregulation, Figure 5(a); Oct4-GFP
colony formation, Figure 5(b)). Therefore, we infected OG2
MEF with retrovirus harboring Klf4 transgene before incu-
bation in the presence or absence of 100nM pTAT-mcMyc
for 5 pretreatment days (designated: 5 days; Figure 5(a)).
Alternatively, MEF remained uninfected and untreated for
the pretreatment period. After 5 days of Klf4 expression ±
recombinantproteintreatment(designatedday0),treatment
groups and untreated MEFs were (i) collected and analysed
by FACS for proportion of Thy1+ cells and (ii) replated
for a second infection of retrovirus for mOct4 and mSox2.
As controls, nontreated MEF were plated for infection with
retrovirus for (i) mOct4 and Sox2 only, (ii) mOct4, mSox2
and mKlf4 only, or (iii) mOct4, mSox2, mKlf4, and mcMyc
(Figure 5). FACS analysis for Thy1+ cells was performed6 Stem Cells International
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Figure 2: Construction and transduction of of pTAT-mcMyc recombinant protein to MEF in vitro. (a) Schematic representation of the
pTAT-mcMyc construct. (b) Reduced and denatured pTAT-mcMyc recombinant protein was resolved on 12–15% SDS-polyacrylamide gel
and transferred to PVDF membrane by electrophoresis (90V, 2 hours, 4◦C). Wet membrane was blocked for 1 hour in Odyssey blocking
buﬀer (1:1 Tris-HCl buﬀer) and probed with either mouse anti-6xHistidine or mouse anti-mouse cMyc primary antibody before detection
with goat anti-mouse Alexa Fluor-680 secondary antibody. Recombinant pTAT-mcMyc was detected at predicted molecular weight (57–
60kDa; arrow). (c) MEFs were plated to coverslips before 100nM pTAT-mcMyc recombinant protein was applied to equilibrated culture
media. Following a 1-hour incubation, MEFs were washed, ﬁxed, blocked, and probed with antibody recognizing 6xHistidine (bottom
panel). Cell nuclei were detected with Hoechst dye (middle panel). Scale bar: 200μM. Red arrows shown detection of pTAT-mcMyc protein
outside of detectable nuclei. (d) MEFs were infected with retrovirus harboring OSK or left uninfected. OSK-expressing MEFs were treated
with 100nM pTAT-mcMyc protein (red square) or pTAT-control protein (green triangle) daily for 12 days. Uninfected MEFs were left as a
control, or treated with 100nM pTAT-mcMyc protein (brown diamond) daily for 12 days. On days 5, 7, 9, and 12 after infection, Oct4-GFP+
colonies were counted in duplicate wells. Mean ± SEM of n = 4 independent experiments shown; P<0.05.Stem Cells International 7
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Figure 3: OSK + pTAT-mcMyc treated MEF display the hallmarks of pluripotency. (A) Schedule for pTAT-mcMyc treatment of somatic
cells. MEF were infected for 24 hours (“I”) before retrovirus was washed from cells (“W”) and pTAT-mcMyc and control recombinant
protein applied (day 0; “P”). Protein was applied daily for 12 days. (B) Oct4-GFP+ clone Tatc1 from Oct4/Sox2/Klf4 + pTAT-mcMycs treated
cells. (C) Conﬁrmation of alkaline phosphatase expression in clone Tatc1. (D) RT-PCR conﬁrms Tatc1 expresses endogenous markers Oct4,
Sox2, cMyc, Klf4, Rex-1, and Nanog (“Endo”). We further conﬁrmed this clone was not contaminated with mcMyc transgene by PCR
using genomic DNA template (“T’gene”; all oligonucleotides outlined elsewhere) [1]. (E) Following injection into SCID mice, Tatc1 form
teratomas with diﬀerentiated cells characteristic of the three germ layers (cartilage characteristic of endoderm, glandular tissue reminiscent
of mesoderm, and neural rosettes characteristic of ectoderm). (F) Immunocytochemistry conﬁrms Tatc1 expresses pluripotency marker
stage-speciﬁc embryonic antigen-1 (SSEA1). (G) Reprogramming of MEF to Tatc1 maintained normal karyotype (40XY). (H) Following
aggregation with 2.5dpc embryos, Oct-GFP+ Tatc1 cells contribute to the inner cell mass (labeled “ICM”) of subsequent 4.5dpc blastocysts
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Figure 4: Thy1 downregulation by OSK, pTAT-mcMyc alone or
OSK+pTAT-mcMyc at 5, 7, 9, and 12 days after infection. MEFs
were infected with retrovirus harboring transgenes for mOct4,
mSox2, and mKlf4 (OSK; orange line). 100nM pTAT-mcMyc
recombinant protein was applied to OSK expressing cells (red line),
or to non-transduced MEFs (brown line). On days 5, 7, 9, and 12
after infection, percentage of cells expressing the ﬁbroblast marker
Thy1 was assessed in all treatment groups by ﬂow cytometry with
results normalized to untreated MEF controls (black line). Mean ±
SEM of n = 2 experiments shown.
on days 0, 7, and 14 after mOct4/mSox2 infection with
percentage Thy1+ cells in each treatment group normalized
tountreatedcontrolMEF.Oct4-GFPcolonycountswerealso
counted at same time points to assess eﬀect of pre/post-
treatment on reporter gene+ colony formation (Figure 5(b)).
As highlighted in Figure 5, ﬁve days pretreatment/ex-
pression of (i) exogenous Klf4 and (ii) exogenous Klf4 + 100
nM pTAT-mcMyc resulted in repression of Thy1 in 20–70%
ofMEF,respectively(designatedday0,Figure 5(a)).Applica-
tion of 100nM pTAT-mcMyc signiﬁcantly enhanced Thy1
repression in Klf4-expressing MEF (P<0.01; Figure 5(a)).
UntreatedMEFwereinfectedwithOS,OSK,orOSKM(pink,
orange, and green lines, resp.) and pretreated MEF were in-
fectedwithOSonly,withpTAT-mcMycpretreatmentcontin-
uing in pretreated MEF (red line).
After7-dayexpression, Thy1repression inOS-and OSK-
infected (only) MEF was modest (in 35–40% of MEF). Thy1
expression was almost completely abolished in MEF infected
with OSKM (i.e., not prereated) at day 0. Continued 100nM
pTAT-mcMyc treatment in Klf4 preinfected/Oct4/Sox2
postinfected MEF elicited continued Thy1 repression to day
7 to a level insigniﬁcantly diﬀerent from MEF expressing all
four reprogramming factors. Interestingly, preinfection with
Klf4 (thus prerepressing Thy1), with subsequent Oct4/Sox2
infection, was equally eﬀective at repressing Thy1 at 14 days
than infecting cells concurrently with OSK (compare blue
and orange lines; Figure 5(a)).
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Figure 5: A staggered approach to application of reprogramming
factors. (a) MEF were pre-treated with mKlf4 (provirus) ± pTAT-
mcMyc protein (or untreated) for 5 days and infected with mOct4
and mSox2 at day 0. Alternatively, MEF were not pre-treated and
infected with mOct4+mSox2, mOct4+mSox2+mKlf4 or all four
reprogramming factors (OSKM). The percentage of Thy1+ MEF
was ascertained relative to untreated MEF at days 0, day 7 and
day14 post-infection.Statisticalsigniﬁcance inpercentage ofThy1+
MEF was assessed by one-way ANOVA. Mean ± SEM of n = 3
experiments shown. (b) Oct4-GFP+ colony counts for experiments
outlined in 6A were counted at days 0, 5, 7, 12, and 14 post-
infection. Mean ± SEM of n = 3 experiments shown.
Concurrent OSKM (signiﬁcant) and concurrent OSK
(insigniﬁcant) infection still yielded more colonies than the
staggered approach adopted above (Figure 5(b)). In fact, few
Oct4-GFP+ colonies were observed for any of the Klf4 ±
100nM pTAT-mcMyc pretreated/Oct4 + Sox2 postinfected
groups. These results suggest that although increased Thy1
repression is achieved through pretreatment with Klf4 ±
100nM pTAT-mcMyc, concurrent infection with all four
reprogramming factors still yields most eﬃcient reporter
gene+ colonies at day 14. At 14 days, pretreatment of
MEF with exogenous Klf4 + 100nM pTAT-mcMyc beforeStem Cells International 9
Oct4/Sox2 infection at day 0, signiﬁcantly repressed Thy1
than cells infected with Oct4/Sox2 alone. However, this eﬀect
is not reﬂected in GFP+ colony counts at day 14.
4. Discussion
Tohighlightthecontributionofeach/combinationsofrepro-
gramming factors, and possible suppressive eﬀects of each
capability to repress Thy1, we infected MEF with individual
reprogramming factors or combinations of factors and
assessed Thy1 at day 12 after infection (Figure 1). Twelve-day
expression of each individual reprogramming factors eﬀec-
tivelydownregulatesThy1(Figure 1).Wefailedtoobservean
additive eﬀect of expressing both Oct4 and Sox2 compared
with expressing either factor alone, or expressing both
cMyc and Klf4 rather than expressing either factor alone.
The capacity of Oct4 or Sox2 to individually downregulate
Thy1 was not signiﬁcantly enhanced when (i) expressed
concurrently, or when (ii) cMyc and Klf4 were also expressed
in the same MEF (Figure 1).
We adopted a recombinant protein delivery approach
to dissect the molecular mechanisms of somatic cell
reprogramming. We describe a method for generating
semisoluble, particulate recombinant mcMyc protein with
an N-terminal linked 11-amino-acid, arginine-rich motif
(49RKKRRQRRR57) of transactivating transcriptional-
activator (Tat) of HIV (Figure 2(a))[ 21, 32]. The TAT and
mcMyc functional domains were coupled through a peptide
linker sequence, reducing interference between these do-
mains [14] .D e t e c t i o no fp T A T - m c M y cp r o t e i nw i t ha n t i -
bodies recognizing either the 6xHistidine leader sequence or
cMyc protein by western blot analysis conﬁrmed expression
and puriﬁcation of in-frame recombinant protein of pre-
dicted molecular weight (Figure 2(b)). Initial experiments
suggested pTAT-mcMyc protein was primarily soluble, and
particulate when resuspended after acetone precipitation
(data not shown). Binding of the Tat domain to heparan
sulfate proteoglycan of cells in vitro initiates rapid (in the
order of minutes) translocation of recombinant protein to
the nuclear compartment (Figure 2(c))[ 15–20, 33].
Notable diﬀerences in protein puriﬁcation and concen-
tration distinguish published reports from the present study,
with recombinant proteins commonly puriﬁed from bacte-
rialinclusionbodiesbeforerefolding[13,14].Kimetal.[12],
expressed proteins in transfected human cells and applied
unknown quantities of unpuriﬁed reprogramming factors
in whole protein extracts to targets cells, with neither study
concentrating recombinant protein fractions/preparations.
Puriﬁcation of soluble, un-denatured protein in the present
study circumvents potential problems associated with mis-
folding of recombinant protein to numerous alternative (and
potentially inactive) conformations, with acetone concen-
tration removing nonprotein bacterial contaminants [14,
34, 35]. Previous attempts to utilize denatured Tat-fusion
protein for reprogramming of human ﬁbroblasts were
hampered by restriction of protein to endocytotic vesicles
[14]. Treatment of target cells in serum-free conditions may
also restricted cytoplasmic vesicular release. Puriﬁcation of
semisoluble, particulate pTAT-mcMyc recombinant protein,
and/or equilibration of culture media before recombinant
protein application, may contribute to escape and/or evasion
of our Tat-fusion proteins from such endocytotic vesicles
[14].
We applied 100nM pTAT-mcMyc protein to uninfected
MEF or OSK-expressing MEF daily for 12 days and mon-
itored Oct4-GFP+ colony formation (Figure 2(d))[ 32, 36,
37]. Contrary to previous reports demonstrating toxicity of
80nM TAT-DsRED-Klf4 application in MEF [14], we failed
to observe adverse eﬀects in MEF cultured in 100nM pTAT-
mcMyc. This may be attributable to cytotoxicity observed
in a number of red ﬂuorescent protein (RFP) variants, or
unexplained toxicity of Klf4 protein itself at these concentra-
tions. Nonetheless, up to day 5 after infection, ES-like Oct4-
GFP+colonies were not observed in any treatment group
(Figure 2(d))[ 9]. Signiﬁcantly accelerated Oct4-GFP+ col-
ony formation was observed in OSK-expressing cells treated
with pTAT-mcMyc at days 7 and 9 after infection. Clone
Tatc1 expressed (Oct4)-GFP and alkaline phosphatase, dif-
ferentiatedtoallgermlayersinteratomas,expressedpluripo-
tency markers (as assessed by RT-PCR and immunocyto-
chemistry), maintained normal karyotype and was capable
of contributing to the inner cell mass of aggregated chimeric
embryos (Figures 3(A)–3(H)). This conﬁrms conversion of
OSK + pTAT-mcMyc recombinant protein-treated MEF to a
fully reprogramming phenotype.
We combined transgene expression ± pTAT-mcMyc re-
combinant protein delivery to highlight mechanisms of
lineage gene repression. Thy1 (CD90) is glycosylphosphati-
dylinositol-anchored plasma membrane glycoprotein ex-
pressed in a variety of cell types (including ﬁbroblast pop-
ulations) implicated in cell proliferation and apoptosis,
cytoskeletal organization, cell-cell/matrix adhesion, and a
number of cytoplasmic signaling cascades [6, 7, 38]. Since
constitutive expression of OSKM transgenes represses Thy1
in the majority of murine ﬁbroblasts, we exploit the ability
to apply controlled concentrations of proteins over deﬁned
periods to highlight mechanisms of Thy1 repression [5]. Five
days of 100nM pTAT-mcMyc recombinant protein treat-
ment (±OSK expression) initiates considerable repression of
Thy1 expression (Figure 4; as assessed by ﬂow cytometry).
OSK transgene expression also elicits downregulation of
Thy1, but at markedly reduced eﬃciency. Surprisingly,
combining OSK expression and pTAT-mcMyc delivery failed
to elicit additive Thy1 repression on OSK alone. This result
suggests that mcMyc primarily mediates Thy1 repression
<5 days in the presence or absence of OSK, overriding or
“saturating” the moderate OSK-mediated repression or is
utilizedpreferentiallywhen“expressed”inthesamecell,thus
suggesting Thy1 repression in the initial stages of repro-
gramming may be rate limiting. Perhaps OSK-mediated
Thy1 repression is the default mechanism for early repro-
gramming, when suﬃcient concentrations of mcMyc are
absent. It is unclear, yet possible, that cMyc directly or indi-
rectly promotes recruitment of histone methyltranferase/s to
the Thy1 promoter to initiate transcriptional repression, or
disrupt cytoskeletal actin bundles to permit cellular mor-
phological changes and adoption of pluripotent phenotype
[38–40]. The transition from Thy1+ to a Thy1− phenotype10 Stem Cells International
in nasopharyngeal mucosa is a feature of carcinogenesis, and
thus suggests that Thy1 represents a candidate as a tumor
suppressor [41]. Given the similarities in genetic proﬁle be-
tween embryonic stem cells and cancer stem cells, it is unsur-
prising that repression of tumour-repressor gene function/
immortalization markedly increases the eﬃciency of somatic
cell reprogramming [42–44]. Lung ﬁbroblast populations
lacking Thy1 have considerably reduced methyltransferase
levels ascertained by real-time PCR, with chemically induced
demethylation of Thy1− ﬁbroblasts reinitiating Thy1 expres-
sion [39].
A gradual trend (although statistically insigniﬁcant) of
Thy1 downregulation is observed in OSK expressing cells
between 5 and 12 days (Figure 4). By contrast, pTAT-mcMyc
protein alone fails to mediate signiﬁcant improvements in
Thy1 downregulation over the same period and is not a sig-
niﬁcant improvement on OSK-mediated Thy1 suppression.
However, addition of 100nM pTAT-mcMyc protein to OSK
provirus-expressing MEF further promotes Thy1 suppres-
sion to 7 days after infection, an improvement approaching
statistical signiﬁcance on OSK alone (P = 0.07; Figure 4).
Acooperativeoradditivemechanismbetween100nMpTAT-
mcMyc and either O ±S ±K may accelerate Thy1 repression
from 5 to 7 days.
The reversibility of recombinant protein delivery, as
well as ability to control the temporal and concentration
aspects of its application, permits the manipulation of the
iPS reprogramming methodology with a view to improving
reprogramming eﬃciency. cMyc is required for the initial
days of reprogramming only (for AP+ colonies), yet Oct4
is required throughout reprogramming [8]. Since lineage
gene repression is an early prerequisite for reprogramming,
we hypothesized a staggered approach, that is, prerepressing
Thy1 through application of Klf4 ± pTAT-mcMyc with sub-
sequent proviral expression of Oct4 and Sox2, could improve
reprogramming eﬃciency, as assessed by Oct4-GFP+ colony
formation. This may also reduce the time required to expose
target cells with reprograming factors, in particular Oct4
and Sox2. Although 5-day application of Klf4 ± pTAT-
mcMyc signiﬁcantly repressed Thy1 at the time of Oct4/Sox2
application (day 0), total Thy1 repression was comparable
to consecutive 4-factor expression at 14 days (Figure 5(a)).
Importantly, pre-repression of Thy1 did not improve Oct4-
GFP+ colony formation (Figure 5(b)). Although Thy1 ex-
pression is repressed with equal eﬀectiveness over 7 and 14
days by (i) consecutive OSKM expression or (ii) staggered
expression Klf4/pTAT-mcMyc and Oct4/Sox2 (Figure 5(a)),
it does not translate to Oct4-GFP+ colony formation at any
time point (Figure 5(b)). In fact, Oct4-GFP+ colony forma-
tion was also delayed in pretreated MEF (Figure 5(b)). These
results suggest although Thy1 repression is a pre-requiste
for subsequent pluripotency gene activation and successful
reprogramming, with cMyc and Klf4 primarily responsible
for mediating this early event (Figures 4 and 5)[ 4, 5, 8],
early coexpression of Oct4 and Sox2 is still required for
timely and eﬃcient reporter gene+ colony formation later in
reprogramming (i.e., 14 days).
To conclude, we have exploited the endocytotic prop-
erties of Tat transduction peptide to rapidly transport key
transcription factors to the nuclei of Oct4-GFP MEF. Exper-
imental results outlined here suggest mcMyc regulates the
initial (<5 days) suppression of Thy1 in MEF, followed by
a cooperative mechanism driven by mcMyc/Klf4 from 5–9
days after infection (Figure 4). Protein delivery can be trans-
duced to mitotically active or inactive cells, or cells that are
diﬃcult to infect with cDNAs (e.g., mesenchymal stem cells),
does not permanently disrupt the host genome and can be
transiently applied to drive reprogramming and is rapidly
reversible. Therefore, we suggest application of additional
Tat fusion constructs at varying concentrations and times
will further highlight the events that characterize somatic
cell reprogramming. As heparan sulfate proteoglycan dis-
play considerable sequence homology between mammalian
species and are ubiquitously expressed throughout many cell
types, the same Tat fusion constructs could potentially be
used in many cells types within and between mammalian
species and be used to generate protein-iPS cells in a con-
trolled manner. We anticipate more studies dedicated to
varying concentrations of recombinant proteins to highlight
threshold levels of reprogramming factors to maximize
somatic cell reprogramming.
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